Acadian Asset Management’s Puma Biotechnology PBYI Stock Holding History

Acadian Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13M	Buy	2,041,759 +16,936	+0.8%	+$109K	0.02%	458
2025 Q4	$12M	Sell	2,024,823 -28,482	-1%	-$151K	0.02%	443
2025 Q3	$10.9M	Buy	2,053,305 +45,159	+2%	+$192K	0.02%	461
2025 Q2	$6.88M	Hold	2,008,146	–	–	0.01%	506
2025 Q1	$5.94M	Buy	2,008,146 +36,018	+2%	+$113K	0.02%	455
2024 Q4	$6.01M	Buy	1,972,128 +3,129	+0.2%	+$9.1K	0.02%	468
2024 Q3	$5.02M	Buy	1,968,999 +17,791	+0.9%	+$53.9K	0.02%	500
2024 Q2	$6.36M	Sell	1,951,208 -5,305	-0.3%	-$23.3K	0.02%	443
2024 Q1	$10.4M	Buy	1,956,513 +39,239	+2%	+$211K	0.04%	291
2023 Q4	$8.3M	Buy	1,917,274 +59,274	+3%	+$196K	0.03%	330
2023 Q3	$4.88M	Sell	1,858,000 -16,123	-0.9%	-$54.9K	0.02%	443
2023 Q2	$6.61M	Sell	1,874,123 -736	-0%	-$2.3K	0.03%	385
2023 Q1	$5.79M	Buy	1,874,859 +61,819	+3%	+$233K	0.03%	420
2022 Q4	$7.67M	Sell	1,813,040 -25,902	-1%	-$89.4K	0.04%	332
2022 Q3	$4.35M	Buy	1,838,942 +30,114	+2%	+$87.9K	0.02%	437
2022 Q2	$5.15M	Buy	1,808,828 +116,929	+7%	+$291K	0.03%	407
2022 Q1	$4.87M	Sell	1,691,899 -54,382	-3%	-$141K	0.02%	472
2021 Q4	$5.3M	Buy	1,746,281 +446,734	+34%	+$1.94M	0.02%	442
2021 Q3	$9.11M	Buy	1,299,547 +72,068	+6%	+$540K	0.03%	331
2021 Q2	$11.3M	Buy	1,227,479 +12,002	+1%	+$122K	0.04%	305
2021 Q1	$11.8M	Buy	1,215,477 +91,945	+8%	+$1.03M	0.05%	304
2020 Q4	$11.5M	Sell	1,123,532 -223,085	-17%	-$2.26M	0.04%	311
2020 Q3	$13.6M	Buy	1,346,617 +79,686	+6%	+$811K	0.06%	264
2020 Q2	$13.2M	Buy	1,266,931 +391,666	+45%	+$4.05M	0.06%	280
2020 Q1	$7.39M	Buy	875,265 +36,143	+4%	+$351K	0.04%	312
2019 Q4	$7.34M	Buy	839,122 +456,921	+120%	+$3.78M	0.03%	367
2019 Q3	$4.11M	Buy	382,201 +127,487	+50%	+$1.38M	0.02%	505
2019 Q2	$3.24M	Buy	254,714 +250,130	+5,457%	+$5.76M	0.02%	482
2019 Q1	$178K	Buy	+4,584	New	+$140K	﹤0.01%	1383

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

OSAM

O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return

Acadian Asset Management's PBYI Position: Q1 2026 in Review

Acadian Asset Management increased its Puma Biotechnology (PBYI) stake by 0.84% in Q1 2026, buying an estimated $109K and bringing the position to 2,041,759 shares worth $13M. The position accounts for 0.02% of the portfolio, ranked #458.

Acadian Asset Management first reported a position in PBYI in Q1 2019 and has held it in 29 quarters since. The position peaked at $13.6M in Q3 2020. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

Acadian Asset Management held 2,041,759 shares of Puma Biotechnology worth $13M as of Q1 2026.
Acadian Asset Management bought 16,936 Puma Biotechnology shares in Q1 2026, an estimated $109K.
Puma Biotechnology made up 0.02% of Acadian Asset Management's portfolio in Q1 2026, its #458 holding.
Acadian Asset Management first reported a position in Puma Biotechnology in Q1 2019 and has held it in 29 quarters since.
Acadian Asset Management's Puma Biotechnology position peaked at $13.6M in Q3 2020.
157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.